Tremelimumab
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-TREMELIMUMAB |
|---|---|
| Tipo | Fármaco |
| Aliaces | - ¿Qué?Тремелімумаб |
| Situación | reviewed 2026-04-26 | pending_clinical_signoff |
| Enfermedades | DIS-HCC |
| Fuentes | SRC-NCCN-HCC-2025 |
Datos sobre drogas
| Clase | Anticuerpo monoclonal IgG2 humano anti-CTLA-4 (ICI) |
|---|---|
| Mecanismo | Blocks CTLA-4 — releases T-cell activation brake at priming phase (synergistic with PD-1/PD-L1 blockade). Single-dose STRIDE regimen with durvalumab in HCC. |
| Dosificación típica | STRIDE: 300 mg IV single priming dose with durvalumab 1500 mg, then durvalumab mono q4w. |
| Ucrania registrada | Falso |
| NSZU reembolsado | Falso |
| Ucrania verificada por última vez | 2026-04-27 |
Advertencias
- EIR graves y fatales (más frecuentes con CTLA-4 que con PD-1)
Notas
CTLA-4 irAE pattern differs from PD-1: earlier onset, more colitis and hypophysitis. Single-priming-dose STRIDE regimen (300 mg tremelimumab once + durvalumab maintenance) has acceptable safety vs older Q4W tremelimumab schedules and superseded prior dosing in HCC. Monitor LFTs / TFTs / cortisol / lipase before each durvalumab maintenance dose; high-dose IV methylprednisolone for G3-4 irAE; permanent discontinuation for myocarditis or recurrent G3 irAE despite steroids. UA access via EAP AstraZeneca / cross-border / self-pay only — not on НСЗУ.
Utilizado por
Contraindications
CI-PEMBROLIZUMAB-AUTOIMMUNE- CI-PEMBROLIZUMAB-AUTOIMMUNE
Esquema terapéutico
REG-DURVA-TREME-STRIDE- Durvalumab + Tremelimumab (STRIDE)